DIHEXA Results Timeline: What Studies Measured, and When

Questions about how quickly a compound "works" assume something the dihexa literature does not currently supply: a body of human trials with scheduled assessment visits. For dihexa, the published record accessible here is preclinical and small. That fact shapes everything else on this page. Rather than a week-by-week chart, what follows is a description of what researchers measured, in which animal models, and at what stage of those experiments.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions about any substance, including research compounds.

The short answer: no human results timeline exists in this evidence set

None of the sources reviewed here described a clinical trial in people with baseline, interim and endpoint visits. The compound appears in animal experiments and in a broader review of peptide therapeutics in orthopaedics that discussed applications, challenges and future directions for the peptide class as a whole (PMID 41490200). When a literature base looks like this, statements of the form "effects appear at week four" have no source to rest on. The honest framing is that the timing of any human response has not been characterised in the cited record.

That is not the same as saying nothing has been measured. It means the measurements came from rodents, on schedules set by the experimental model, and those schedules describe laboratory protocols rather than expectations for a person.

How preclinical timelines are built, and why they differ from human ones

Animal studies generally fix three things in advance: an induction or injury phase, a treatment phase, and an assessment phase. The assessment phase can be a single terminal measurement or a series of repeated tests. A toxin-induced disease model and a surgical nerve-repair model sit at opposite ends of that spectrum: the first often compresses symptom onset into days, while the second unfolds over the slower biology of axonal regrowth.

Because of this, "how long did it take" is not one question in preclinical work. It is at least three:

• How long was the compound administered before any outcome was recorded.
• How long after injury or induction the assessment occurred.
• Whether outcomes were sampled repeatedly or only once at the end.

Readers reconstructing a timeline from abstracts alone will usually find the third question unanswered, which is why the summaries below stay close to what the titles and abstracts state and stop where the record stops.

Rodent model 1: an angiotensin IV analog in a Huntington's-disease-like model

Dihexa is commonly described in the literature as an angiotensin IV analog, and a 2024 report in the Journal of Huntington's Disease examined the effects of an angiotensin IV analog on 3-nitropropionic acid-induced Huntington's-disease-like symptoms in rats (PMID 38489193). The study was conducted in rats, and the outcome domain named in the record was Huntington's-disease-like symptoms produced by 3-nitropropionic acid rather than any cognitive or performance measure in humans (PMID 38489193).

What that tells a reader about timing

The 3-nitropropionic acid model is a chemically induced model, which means symptom onset is driven by the toxin schedule rather than by spontaneous disease progression. The relevant "clock" in such an experiment is therefore the toxin administration schedule, and any treatment effect is read against that. What the cited record establishes is that researchers measured symptoms in this induced model after exposure to an angiotensin IV analog (PMID 38489193); it does not establish a latency period that could be transferred to a human timeline.

Anyone wanting the exact administration schedule, the number of animals, the direction and size of the reported effects, and the statistical handling should read the full text rather than rely on any summary, including this one.

Rodent model 2: limb function recovery after sciatic nerve damage and repair

A 2021 experimental animal study in Annals of Medicine and Surgery evaluated stem cells, granulocyte-colony stimulating factor and/or dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model (PMID 34703584). The design named in that record is a combination design: single agents and combinations were compared within the same injury-and-repair model, with limb function recovery as the outcome of interest (PMID 34703584).

Why this is the closest thing to a "timeline" in the set

Peripheral nerve repair models are inherently longitudinal. Function cannot be assessed the day after surgery in any meaningful way, because regeneration and reinnervation take time; recovery-of-function endpoints in this model class are repeated-measures outcomes by construction. So while the abstract-level record does not spell out a published week-by-week schedule, the study's outcome — limb function recovery after nerve damage and repair in rats (PMID 34703584) — belongs to a category of measurement that unfolds over a post-surgical follow-up period rather than within hours.

That distinction matters. A reader searching for "when do effects appear" is usually asking about a subjective human experience. The measurement in this study was an objective functional outcome in an animal after a surgical intervention, which is a different construct entirely.

Where dihexa sits in the broader peptide translation picture

A 2026 review in JAAOS Global Research & Reviews surveyed therapeutic peptides in orthopaedics, covering applications, challenges and future directions for the field (PMID 41490200). Reviews of this type are useful for timeline questions in an indirect way: they document how far a peptide class has moved from bench models toward clinical use, and they identify the challenges that stand between the two (PMID 41490200).

For a compound whose accessible published evidence is rodent-based, the practical consequence is that no regulatory-grade efficacy timeline has been established. Many peptides discussed in public forums are handled as research chemicals rather than approved products, and research-use-only labelling means a substance has not been evaluated for human administration by a regulator.

What was measured, and in what model

Why week-by-week expectations cannot be built from this literature

Several gaps block the translation from these records to a human calendar:

1. Species. Both outcome studies were conducted in rats (PMID 38489193, PMID 34703584). Rodent pharmacokinetics, metabolism and repair biology do not scale linearly to humans.
2. Model specificity. A toxin-induced neurodegeneration model and a transected-and-repaired nerve are highly artificial systems designed to produce measurable pathology quickly; neither models ordinary human physiology.
3. Combination confounding. In the sciatic nerve study, dihexa was examined alongside stem cells and granulocyte-colony stimulating factor (PMID 34703584), so any group-level finding has to be read with the combination structure in mind.
4. No clinical endpoints. Nothing in this set reports human cognition, mood, memory or recovery scores over weeks.

Taken together, the three records reviewed here describe preclinical measurement and class-level discussion rather than a clinical results schedule (PMID 34703584, PMID 41490200).

Adverse Events: What Studies Report

The verified sources here are not safety studies, and none of them reported a characterised human adverse-event profile for dihexa over time. The 2026 orthopaedic peptide review discussed challenges facing peptide therapeutics as a category, which is where questions of safety, manufacturing and regulatory status are typically framed (PMID 41490200). The rat studies were designed around efficacy-type outcomes — symptoms in an induced Huntington's model (PMID 38489193) and limb function recovery after nerve repair (PMID 34703584) — rather than around systematic toxicology in humans. Absence of reported adverse events in a small preclinical set is not evidence of safety; it reflects what those studies were built to measure.

Questions the published record has not answered

• Whether any effect observed in rats occurs in humans at all.
• What a human exposure-response relationship looks like over days, weeks or months.
• Whether any measured change persists, plateaus or reverses after administration stops.
• How dihexa behaves alongside other agents outside the specific combination tested in the rat nerve-repair work (PMID 34703584).
• Long-term safety in any species over extended exposure.

How to read future dihexa timeline claims

When a new claim about timing appears, a few structural checks separate evidence from assertion: whether the source is a human trial or an animal study; whether outcomes were measured at pre-specified timepoints or reported post hoc; whether the compound was given alone or in combination; and whether the endpoint was objective or self-reported. Applying those checks to the current set returns a consistent answer — rodent models, small evidence base, no human schedule (PMID 38489193).

Related reading

For background on what dihexa is, how it is described in the literature and its regulatory status, see the DIHEXA overview.

References

• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews, 2026)
• Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats (Journal of Huntington's Disease, 2024)
• Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies (Annals of Medicine and Surgery, 2021)